Spectrum Pharmaceutecals Inc (SPPI)

[Ville7]

Poziotinib

Hey antihama,

the korean phase II breast cancer data we will see at ESMO must be good or very good.

EXEL first had a proffered poster presentation last year with their CaboSun Study. They even got promoted to a presidential session because the data was practice changing. They showed that their drug is significantly better than the first line treatment in RCC sunitinib.

So i expect SPPI to go higher from here - technical breakout above USD 8.

If you know me back from the Yahoo message board you know i am not a fan of Raj, the ultimative pusher, but with poziotinib he may be onto something this time. In NSCLC and BC.

We will get a dilution soon, but with rolontis and poziotinib much better years could be ahead.

Ville